OPKO Health: Q1 Earnings Insights

Shares of OPKO Health OPK rose in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 155.56% over the past year to $0.05, which were in line with the estimate of $0.05.

Revenue of $545,200,000 rose by 157.78% year over year, which beat the estimate of $498,460,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

OPKO Health hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Apr 28, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/c2fhv5z7

Technicals

Company's 52-week high was at $6.47

Company's 52-week low was at $1.91

Price action over last quarter: down 11.64%

Company Description

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!